Sciensus

Sciensus (formerly Healthcare at Home) is a global life sciences business established in 1992 by founder and former chairman Charles Walsh based in London.

The company supplies a wide range of specialist medications and patient support programmes for chronic, cancer and rare disease patients, with around 1,600 employees dealing with more than 230,000 patients a year. It works with every NHS trust in the UK.

In Spring 2015, Healthcare at Home reverted to using in house logistics rather than working with a third party for all deliveries.

In Autumn 2015, the company went through a full corporate rebranding, including new logos, literature, strap line and website in an attempt to re-establish the company's status in the market.

The company's name was changed in 2022 from "Healthcare at Home LTD" to "Sciensus Pharma Limited", using only "Sciensus" to refer to themselves from then on.

In July 2023, 1 patient died and 3 were hospitalised after being administered unlicensed versions of cabazitaxel chemotherapy provided by Sciensus. This follows reports in May 2023 of complaints of poor service and delays raised about the company, sparking a possible CQC review. This resulted in "partial suspension" of its licence by the Medicines and Healthcare products Regulatory Agency (MHRA).